Filing Flows › Industrials › NRC Health (NRC)
NRC Health (NRC) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · NRC Health (NRC) Q3 2026 earnings results →
Q3 2026 Revenue up 11% year over year to $38.4M · 12¢ of every $1 of revenue kept as net profit · operating margin 23.2%
NRC Health made $38.4M in Q3 2026 (+11% Y/Y). Operating margin 23.2%, net earnings $4.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $38.4M in Q3 2026, up 11% year over year and up 8% from the previous quarter.
Operating profit was $8.9M, a 23.2% margin (up 0.8 points year over year). Of the extra revenue versus Q3 2025, 31% reached operating profit, above the 22% margin then. Total costs grew 10% against revenue growth of 11%. The fastest-growing cost line was Other operating costs (+20%). Net earnings were $4.7M, up 14% year over year. The effective tax rate was 36.4%.
Operating cash flow was $8.0M (down 42% year over year), 170% of net earnings. Non-cash charges added back $2.1M of depreciation and amortization. Working capital and other items added $1.2M. After capital expenditures ($1.0M), free cash flow as the company reports it was $7.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $38.4M | +11% | 23.2% | $4.7M | $8.0M |
| Q2 2026 | 10-Q | Aug 4, 2026 | $35.4M | +4% | -9.1% | −$3.3M | $1.4M |
| Q1 2026 | 10-Q | May 6, 2026 | $34.8M | +4% | 16.0% | $3.2M | $7.2M |
| Q4 2025 | 10-K | Mar 5, 2026 | $35.2M | -5% | 13.3% | $1.7M | $7.2M |
| Q3 2025 | 10-Q | Nov 7, 2025 | $34.6M | -3% | 22.4% | $4.0M | $13.8M |
| Q2 2025 | 10-Q | Aug 8, 2025 | $34.0M | -3% | 4.7% | −$106K | −$1.1M |
| Q1 2025 | 10-Q | May 9, 2025 | $33.6M | -5% | 25.6% | $5.8M | $6.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About NRC Health
For more than 45 years, NRC Health (NASDAQ: NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health’s commitment to Human Understanding® helps leading healthcare systems get to know the patients, families, consumers, employees, and communities they serve on a human level. Guided by its uniquely empathic heritage, human-centered approach, unmatched national market research, and emphasis on consumer preferences, NRC Health is transforming the healthcare experience, creating strong outcomes across the healthcare journey. For more information, email info@nrchealth.com, or visit www.nrchealth.com.
In its own words, from its 8-K, filed Jul 28, 2026.
NRC Health against its Services-Commercial Physical & Biological Research peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +11% against the peers' median +8%. Operating margin: 23.2% against the peers' median 12.9%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| NRC NRC Health | Q3 2026 | $38.4M | +11% | 23.2% |
| IQV IQVIA Holdings | Q3 2026 | $4.4B | +8% | 12.9% |
| INCY Incyte | Q3 2026 | $1.6B | +14% | -45.5% |
| CRL Charles River Laboratories International | Q3 2026 | $983M | -2% | 20.6% |
| MEDP Medpace Holdings | Q3 2026 | $716M | +8% | 23.1% |
| MXCT Maxcyte | Q2 2026 | $7.3M | -14% | -140.7% |
| FOXO Foxo Technologies | Q2 2026 | $4.7M | -10% | 185.5% |
| OABI OmniAb | Q3 2026 | $4.0M | +78% | -409.9% |
| BIAF bioAffinity Technologies | Q3 2026 | $1.1M | -26% | -328.0% |
Source: NRC Health 10-Q on SEC EDGAR · CIK 70487 · Services-Commercial Physical & Biological Research
Guidance and outlook
13F: who owns NRC and who is buying
More on NRC
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results